R-Crio | Stem Cells

r-crio.com

R-Crio S.A. is a company specialized in cryopreservation of adult stem cells from the pulp of deciduous (baby) teeth. R-Crio was founded in 2013 by Dr. José Ricardo Muniz Ferreira, after a decade of research involving biomaterials and stem cells in regenerative medicine and tissue bioengineering in collaboration with researchers from high-ranking universities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

news image

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More

METASTASIS BLOCKING ANTIBODY SHOWS PRECLINICAL PROMISE

Genetic Engineering and Biotechnology News | April 24, 2020

news image

Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently in EMBO Molecular Medicine through an article entitled “Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody”—s...

Read More

INDUSTRIAL IMPACT

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

news image

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More

MEDICAL

TARGETING CHRONIC INFECTIONS IN CYSTIC FIBROSIS, CYSTIC FIBROSIS FOUNDATION INVESTED IN FELIX BIOTECHNOLOGY

Felix Biotechnology | March 07, 2022

news image

Felix Biotechnology, a biopharmaceutical business focusing on developing first-in-class, long-lasting antibacterial medicines to treat chronic drug-resistant infections, announced that it has received a Therapeutics Development Award from the Cystic Fibrosis Foundation. The funding will aid Felix's efforts to develop a novel medication to treat chronic Pseudomonas aeruginosa lung infections. Chronic P. aeruginosa infections affect half of the persons with cystic fibrosis, many...

Read More
news image

CELL AND GENE THERAPY

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More
news image

METASTASIS BLOCKING ANTIBODY SHOWS PRECLINICAL PROMISE

Genetic Engineering and Biotechnology News | April 24, 2020

Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently in EMBO Molecular Medicine through an article entitled “Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody”—s...

Read More
news image

INDUSTRIAL IMPACT

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More
news image

MEDICAL

TARGETING CHRONIC INFECTIONS IN CYSTIC FIBROSIS, CYSTIC FIBROSIS FOUNDATION INVESTED IN FELIX BIOTECHNOLOGY

Felix Biotechnology | March 07, 2022

Felix Biotechnology, a biopharmaceutical business focusing on developing first-in-class, long-lasting antibacterial medicines to treat chronic drug-resistant infections, announced that it has received a Therapeutics Development Award from the Cystic Fibrosis Foundation. The funding will aid Felix's efforts to develop a novel medication to treat chronic Pseudomonas aeruginosa lung infections. Chronic P. aeruginosa infections affect half of the persons with cystic fibrosis, many...

Read More